Animal Models of Psychosis in Alzheimer Disease

Josh M. Krivinko, Jeremy Koppel, Alena Savonenko, Robert A. Sweet

Research output: Contribution to journalReview article

Abstract

Psychosis in Alzheimer Disease (AD) represents a distinct clinicopathologic variant associated with increased cognitive and functional morbidity and an accelerated disease course. To date, extant treatments offer modest benefits with significant risks. The development of new pharmacologic treatments for psychosis in AD would be facilitated by validated preclinical models with which to test candidate interventions. The current review provides a brief summary of the process of validating animal models of human disease together with a critical analysis of the challenges posed in attempting to apply those standards to AD-related behavioral models. An overview of phenotypic analogues of human cognitive and behavioral impairments, with an emphasis on those relevant to psychosis, in AD-related mouse models is provided, followed by an update on recent progress in efforts to translate findings in the pathophysiology of psychotic AD into novel models. Finally, some future directions are suggested to expand the catalogue of psychosis-relevant phenotypes that may provide a sturdier framework for model development and targets for preclinical treatment outcomes.

Original languageEnglish (US)
JournalAmerican Journal of Geriatric Psychiatry
DOIs
StatePublished - Jan 1 2019

Fingerprint

Psychotic Disorders
Alzheimer Disease
Animal Models
Animal Disease Models
Morbidity
Phenotype

Keywords

  • Alzheimer disease
  • animal model
  • dementia
  • mouse
  • preclinical
  • Psychosis

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Animal Models of Psychosis in Alzheimer Disease. / Krivinko, Josh M.; Koppel, Jeremy; Savonenko, Alena; Sweet, Robert A.

In: American Journal of Geriatric Psychiatry, 01.01.2019.

Research output: Contribution to journalReview article

@article{c8ea77f28ac14536bb6cbec5eb315f45,
title = "Animal Models of Psychosis in Alzheimer Disease",
abstract = "Psychosis in Alzheimer Disease (AD) represents a distinct clinicopathologic variant associated with increased cognitive and functional morbidity and an accelerated disease course. To date, extant treatments offer modest benefits with significant risks. The development of new pharmacologic treatments for psychosis in AD would be facilitated by validated preclinical models with which to test candidate interventions. The current review provides a brief summary of the process of validating animal models of human disease together with a critical analysis of the challenges posed in attempting to apply those standards to AD-related behavioral models. An overview of phenotypic analogues of human cognitive and behavioral impairments, with an emphasis on those relevant to psychosis, in AD-related mouse models is provided, followed by an update on recent progress in efforts to translate findings in the pathophysiology of psychotic AD into novel models. Finally, some future directions are suggested to expand the catalogue of psychosis-relevant phenotypes that may provide a sturdier framework for model development and targets for preclinical treatment outcomes.",
keywords = "Alzheimer disease, animal model, dementia, mouse, preclinical, Psychosis",
author = "Krivinko, {Josh M.} and Jeremy Koppel and Alena Savonenko and Sweet, {Robert A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jagp.2019.05.009",
language = "English (US)",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Animal Models of Psychosis in Alzheimer Disease

AU - Krivinko, Josh M.

AU - Koppel, Jeremy

AU - Savonenko, Alena

AU - Sweet, Robert A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Psychosis in Alzheimer Disease (AD) represents a distinct clinicopathologic variant associated with increased cognitive and functional morbidity and an accelerated disease course. To date, extant treatments offer modest benefits with significant risks. The development of new pharmacologic treatments for psychosis in AD would be facilitated by validated preclinical models with which to test candidate interventions. The current review provides a brief summary of the process of validating animal models of human disease together with a critical analysis of the challenges posed in attempting to apply those standards to AD-related behavioral models. An overview of phenotypic analogues of human cognitive and behavioral impairments, with an emphasis on those relevant to psychosis, in AD-related mouse models is provided, followed by an update on recent progress in efforts to translate findings in the pathophysiology of psychotic AD into novel models. Finally, some future directions are suggested to expand the catalogue of psychosis-relevant phenotypes that may provide a sturdier framework for model development and targets for preclinical treatment outcomes.

AB - Psychosis in Alzheimer Disease (AD) represents a distinct clinicopathologic variant associated with increased cognitive and functional morbidity and an accelerated disease course. To date, extant treatments offer modest benefits with significant risks. The development of new pharmacologic treatments for psychosis in AD would be facilitated by validated preclinical models with which to test candidate interventions. The current review provides a brief summary of the process of validating animal models of human disease together with a critical analysis of the challenges posed in attempting to apply those standards to AD-related behavioral models. An overview of phenotypic analogues of human cognitive and behavioral impairments, with an emphasis on those relevant to psychosis, in AD-related mouse models is provided, followed by an update on recent progress in efforts to translate findings in the pathophysiology of psychotic AD into novel models. Finally, some future directions are suggested to expand the catalogue of psychosis-relevant phenotypes that may provide a sturdier framework for model development and targets for preclinical treatment outcomes.

KW - Alzheimer disease

KW - animal model

KW - dementia

KW - mouse

KW - preclinical

KW - Psychosis

UR - http://www.scopus.com/inward/record.url?scp=85068169242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068169242&partnerID=8YFLogxK

U2 - 10.1016/j.jagp.2019.05.009

DO - 10.1016/j.jagp.2019.05.009

M3 - Review article

C2 - 31278012

AN - SCOPUS:85068169242

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

ER -